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Tacrolimus for induction therapy of diffuse proliferative lupus
nephritis: An open-labeled pilot study.
Background. Tacrolimus is a relatively new calcineurin in-
hibitor that has been increasingly used in transplant medicine.
The objective of the current work is to report our preliminary
experience with tacrolimus in the treatment of diffuse prolifera-
tive glomerulonephritis in systemic lupus erythematosus (SLE).
Methods. Nine consecutive patients who fulfilled the Ameri-
can College of Rheumatology criteria for SLE and with biopsy-
proven diffuse proliferative glomerulonephritis were recruited
for an open-labeled trial with prednisolone and oral tacrolimus
(0.1 mg/kg/day for 2 months, followed by 0.06 mg/kg/day).
Prospective data on renal response and serologic lupus activ-
ity were collected. The efficacy and safety of this regimen was
reported.
Results. Baseline characteristics of the patients were: mean
age 33.3 ± 12 years, women to men ratio 2:1, serum creatinine
94.2 ± 46 umol/L, daily proteinuria 4.56 ± 2.4 g, seven (78%)
patients were nephrotic, three (33%) were hypertensive, and
four (44%) had elevated serum creatinine at the time of re-
nal biopsy. At 6 months of therapy, complete and partial renal
response was achieved in six (67%) and two (22%) patients, re-
spectively. Significant improvement in proteinuria, hemoglobin,
serum albumin, and C3 levels was observed in comparison with
baseline values, starting at the second month. Tacrolimus was
generally well tolerated, except for two patients who developed
transient hyperglycemia. Infective complications, amenorrhea,
hypertrichosis, gingivitis, new-onset hypertension, and signifi-
cant increase in serum creatinine were not reported.
Conclusion. Tacrolimus is an effective option for induction
treatment of SLE-diffuse proliferative glomerulonephritis. Fur-
ther trials are necessary to determine the optimal dosage and
duration of therapy, and its efficacy in comparison to standard
regimens.
Glomerulonephritis is a major manifestation of sys-
temic lupus erythematosus (SLE). Up to 60% of patients
with SLE develop renal involvement at some stage of
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their illness [1, 2]. Diffuse proliferative type of lupus
glomerulonephritis [World Health Organization (WHO)
class IV] carries the worst prognosis and the standard
treatment is a combination of corticosteroid and pulse cy-
clophosphamide [3]. However, cyclophosphamide is not
ideal in terms of efficacy and toxicity. The best initial re-
sponse rate that can be achieved with either intravenous
or oral cyclophosphamide is 82% [4]. Moreover, ovarian
failure is a major concern, particularly with the daily oral
cyclophosphamide regimen [5]. Thus, less toxic treatment
modalities with at least equal efficacy are necessary.
Tacrolimus is a T-cell–specific calcineurin inhibitor
that shares similar immunosuppressive actions with cy-
closporin A (CsA). It complexes with immunophilin
FK506 binding protein 12, and inhibits the phosphatase
activity of calcineurin, resulting in decreased interleukin
(IL)-2 transcription and inhibition of T-cell activation
[6]. In addition, tacrolimus is also capable of inhibiting
the production of tumor necrosis factor-a (TNF-a) and
interferon-c (IFN-c) by activated T cells [7]. In vivo and
in vitro studies have shown that tacrolimus is 10 to 100
times more potent than CsA in its actions [6].
In solid organ tranplantation, tacrolimus is at least
as effective as, or even more effective than CsA in the
prevention of acute and chronic allograft rejection [8,
9]. Moreover, tacrolimus provides effective rescue ther-
apy for transplant recipients who develop chronic allo-
graft rejection or drug-related toxicities associated with
CsA [10]. In an animal model of heart transplantation,
tacrolimus has been shown to be more effective than
CsA in inhibiting IL-10 production and hence revers-
ing ongoing allograft rejection [11]. As IL-10 may have a
deleterious effect on lupus activity [12], tacrolimus may
theoretically be more effective than CsA in SLE.
Tacrolimus has been shown to be effective in rheuma-
toid arthritis [13]. In the lupus-prone mice, treatment
with tacrolimus treatment delayed the onset and progres-
sion of renal disease [14, 15]. However, the experience
of tacrolimus in human SLE is very limited. A few case
reports have described the successful use of tacrolimus
in refractory lupus manifestations that included lupus
nephritis [16, 17]. Tacrolimus ointment has been shown to
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be effective for severe refractory cutaneous lupus lesions
[18]. We conducted a pilot open-labeled study on the effi-
cacy and safety of tacrolimus for the induction treatment
of diffuse proliferative lupus nephritis.
METHODS
An open-labeled prospective study on the efficacy and
safety of tacrolimus in patients with lupus nephritis was
started in June 2003. The inclusion criteria were as fol-
lows: (1) age ≥18 years; (2) diagnosis of SLE fulfilling
four or more of the American College of Rheumatol-
ogy criteria for the classification of SLE [19]; (3) renal
biopsy-proven active diffuse proliferative lupus nephri-
tis (WHO class IV) [20]; (4) initial serum creatinine
level of <200 umol/L; and (5) informed consent ob-
tained from the patients. Exclusion criteria were (1) preg-
nancy; (2) initial serum creatinine level ≥200 lmol/L;
(3) previous treatment with either CsA or tacrolimus;
and (4) known allergy to the calcineurin inhibitors.
Patients who consented for the study were treated with
a protocol consisting of prednisolone and tacrolimus for
6 months. Prospective data on renal response and SLE
activity were collected. Patients were followed at monthly
interval, or more frequently when necessary.
Treatment protocol
Corticosteroid. All patients were treated with oral
prednisolone (0.6 mg/kg/day) for 6 weeks. After that, the
daily prednisolone dose was tapered by 5 mg per week
until a dose of ≤10 mg/day and maintained throughout
the study period.
Tacrolimus. The initial dose was 0.1 mg/kg/day admin-
istered orally in two divided doses with an empty stomach.
Beginning from the third month, the dose of tacrolimus
was reduced to 0.06 mg/kg/day and maintained until the
end of 6 months.
Other drugs. Antimalarials could be used at the dis-
cretion of attending physicians for joint and skin dis-
ease. However, the use of angiotensin-converting enzyme
(ACE) inhibitors and nonsteroidal anti-inflammatory
drugs (NSAIDs) was prohibited during the study period.
Other antihypertensive agents could be used to bring
down the blood pressure to 130/85 mm Hg or less.
Monitoring and dosage adjustment of tacrolimus
The serum creatinine was monitored at each clinic visit.
If the serum creatinine level increased by more than 40%
compared with baseline or by more than 30% compared
with the preceding clinic visit, blood test would be re-
peated. If similar result was obtained, tacrolimus would
be withheld for 2 weeks. At the discretion of the attend-
ing physicians, tacrolimus at a lower dosage would be
resumed if there was an improvement in the serum crea-
tinine level.
At any time of the study, the dosage of tacrolimus could
be adjusted even if the increase in serum creatinine was
not up to the degree described above or when patients
experienced adverse effects.
The trough (predose) whole blood tacrolimus level was
routinely checked for all tacrolimus users at week 4 of the
study. The test could be repeated whenever indicated.
Treatment response at 6 months
Clinical response was classified into complete response,
partial response, and no response at 6 months posttreat-
ment. Complete response was defined as stabilization or
improvement in serum creatinine level with reduction of
proteinuria to <1 g/day, improvement in C3 level and
complete resolution of active urinary casts. Partial re-
sponse was defined as stabilization or improvement in
serum creatinine level with reduction of proteinuria (if
nephrotic range at baseline, a ≥50% decrease in protein-
uria, and <3g/day; if nonnephrotic at baseline, a decrease
to ≤50% of the pretreatment value but >1 g/day), im-
provement in C3 level and reduction in active urinary
casts (≤5/high-power field). No response referred to de-
terioration of serum creatinine level exclusive of other
causes (such as sepsis, nephrotoxic agents, overdiuresis,
and renal vein thrombosis), an increase in proteinuria, or
a reduction in proteinuria but not to the extent of com-
plete response or partial response, or persistence of active
urinary casts (>5/high-power field).
Assessment of SLE activity
Renal and extrarenal disease activity of SLE was mea-
sured using the validated Systemic Lupus Erythemato-
sus Disease Activity Index (SLEDAI) [21]. The SLEDAI
scores at the time of renal biopsy and at 6 months after
treatment were obtained and compared.
Laboratory methods
Antinuclear antibody (ANA) was determined by in-
direct immunofluorescence. Anti-double-stranded DNA
(dsDNA) antibody was tested by the crithidia assay.
Antiextractable nuclear antigen (ENA) antibodies (Ro,
La, nRNP, and Sm) were studied by counterimmuno-
electrophoresis (CIEP). Serum C3 level was measured
by nephelometry. The whole blood tacrolimus level was
measured by using a microparticle enzyme immunoassay
(MEIA) (Abbott Laboratories, Abbott Park, IL, USA).
Statistical analyses
Unless stated otherwise, values were expressed as
mean ± SD (standard deviation). Comparison of vari-
ous parameters between baseline and at different time
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Table 1. Baseline characteristics of patients treated with tacrolimus
Number (%), mean ± SD
Age at lupus nephritis years 33.3 ± 12
Number of women 6 (67)
Systemic lupus erythematous duration
months
46.2 ± 38






Anti-double-stranded DNA 8 (89)
Antiextractable nuclear antigen 7 (78)
Hemoglobin g/dL 9.7 ± 1.6
Serum creatinine lmol/L 94.2 ± 46
Creatinine clearance mL/min 89.3 ± 38
Serum albumin g/L 27.8 ± 5.6
Serum C3 level mg/dL 0.54 ± 0.2
Proteinuria g/day 4.56 ± 2.4
Nephrotic syndrome 7 (78)
Active urinary casts 4 (44)
Creatinine clearance <60 mL/min 3 (33)






intervals was performed by the Wilcoxon matched pair
analysis. Statistical significance was defined as a P value
of less than 0.05, two-tailed. All statistical analyses were
performed using the SPSS program, version 11.5 (SPSS,
Chicago, IL, USA) for Windows XP.
RESULTS
Patient characteristics
Between June 2003 and February 2004, nine patients
(six women and three men) with diffuse proliferative
glomerulonephritis consented for the study. The mean
age was 33.3 ± 12 years and the duration of SLE was
46.2 ± 38 months. Seven (78%) patients were nephrotic,
three (33%) were hypertensive, and four (44%) had el-
evated serum creatinine (>106 lmol/L) at the time of
renal biopsy. The mean histologic activity and chronicity
scores were 7.8 ± 1.9 and 1.5 ± 1.3, respectively. Table 1
shows the baseline characteristics, renal parameters, and
extrarenal features of the patients.
Response to treatment
All patients completed the study protocol with no early
withdrawals. At the end of 6 months, six (67%) patients
responded completely according to our predefined cri-
teria and two (22%) achieved partial response. Signifi-
cant improvement in proteinuria, serum C3, albumin and
hemoglobin levels was observed in the patients, starting
from the second month (Table 2) (Figs. 1 to 3). Serum
creatinine and creatinine clearance was stabilized. Three
(33%) patients had seroconversion of anti-dsDNA. The
improvement in SLEDAI scores was also significant.
Tacrolimus level
We did not have a target therapeutic tacrolimus level
for dosage titration. We ensured that the level was above
3 ng/mL for drug compliance. The mean whole blood
tacrolimus levels in complete, partial, and no response
were 5.9 ± 2.5, 11.7 ± 4.9, and 7.2 ng/mL, respectively.
No definite correlation was found between efficacy and
the trough tacrolimus level.
Adverse events
Table 3 shows the adverse events experienced by our
patients during the study period. Two patients devel-
oped transient hyperglycemia, which was controlled with
oral hypoglycemic agents. Hyperglycemia did not per-
sist when the doses of tacrolimus and prednisolone were
reduced. Neither patients required long-term drug or in-
sulin treatment. One patient complained of hand tremor
which subsided after reduction of tacrolimus dosage. No
patients had new onset hypertension, hypertrichosis, or
gum hypertrophy at the end of the study. One patient
had increase in serum creatinine by 30% compared with
baseline. This was attributed to treatment failure (no re-
sponse) rather than the effect of tacrolimus. None of
the patients developed prolonged amenorrhea or hem-
orrhagic cystitis. The mean tacrolimus levels at week 4
were higher in the three patients who developed either
neurologic or metabolic side effects than the other pa-
tients, but the difference was not statistically significant
(10.1 ± 4.5 vs. 5.9 ± 2.6 ng/mL) (P = 0.26).
DISCUSSION
This is a pilot study of the safety and efficacy of oral
tacrolimus for the initial treatment of diffuse prolifer-
ative lupus glomerulonephritis. Our preliminary results
show that tacrolimus, in conjunction with corticosteroid,
is an effective option for the induction therapy of dif-
fuse proliferative lupus glomerulonephritis. The response
rate of renal disease at 6 months is comparable to our
previous experience with intravenous pulse cyclophos-
phamide [22]. Tacrolimus is generally safe and well tol-
erated, except for two patients who developed transient
hyperglycemia which required close surveillance. As hy-
perglycemia is pretty uncommon during high dose corti-
costeroid treatment in patients with SLE, this metabolic
adverse effect is probably caused by tacrolimus. At the
current dosage, tacrolimus is not associated with hy-
pertrichosis, gum hypertrophy, new onset hypertension,
and significant increase in serum creatinine. Unlike cy-
clophosphamide, prolonged amenorrhea or hemorrhagic
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Table 2. Changes in biochemical parameters after treatment
1 Baseline Month 2 Month 4 Month 6
Daily proteinuria g 4.56 ± 2.4 2.32 ± 1.8a 1.67 ± 1.4a 1.28 ± 0.9a
Nephrotic syndrome number (%) 7 (78) — — 1 (11)a
Serum albumin g/L 27.8 ± 5.6 34.3 ± 5.8b 37.4 ± 4.6b 36.6 ± 4.1b
Serum C3 mg/dL 0.54 ± 0.2 0.84 ± 0.2a 0.86 ± 0.2a 0.82 ± 0.2a
Serum creatinine lmol/L 94.2 ± 46 89.2 ± 40 88.8 ± 32 85.6 ± 30
Creatinine clearance mL/min 89.3 ± 38 85.1 ± 39 83.0 ± 26 88.8 ± 32
Hemoglobin g/dL 9.7 ± 1.6 11.5 ± 1.6a 12.0 ± 0.9a 11.6 ± 1.0a
SLEDAI scores 14.2 ± 2.7 — — 5.1 ± 3.5b
SLEDAI is systemic lupus erythematosus disease activity index.
aP < 0.05 when compared to baseline values.
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Fig. 2. Changes in serum albumin levels after treatment.
cystitis is not observed. The lower incidence of hyper-
trichosis, gum hypertrophy, hypertension, and hyperlipi-
demia related to tacrolimus as compared to CsA are the
potential advantages of the drug when used in young pa-
tients with SLE.
However, there are several limitations of this pilot
trial. First, the sample size is small and data were con-
fined to 6 months. The observed efficacy of the present
combination regimen might well be contributed by pred-
nisolone per se. A longer period of observation on renal
flares and renal function preservation is necessary. Sec-
ond, we have excluded patients with serum creatinine
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Fig. 3. Changes in serum C3 levels after treatment.
Table 3. Adverse events experienced by our patients
Adverse effects Number (%)
Herpes zoster 0 (0)
Major infection (hospitalization) 0 (0)
Amenorrhea >2 months 0/6 (0)
Alopecia 2 (22)
Transient hyperglycemiaa 2 (22)
Nausea, vomiting 0 (0)
Diarrhea 0 (0)
Hemorrhagic cystitis 0 (0)
Cervical dysplasia 0/6 (0)
New onset hypertension 0 (0)
Neurotoxicity (e.g., tremor) 1 (11)
Hypertrichosis 0 (0)
Gingivitis/gum hypertrophy 0 (0)
Increase in serum creatinine by 30%b 1 (11)
aSubsided after tapering of prednisolone and reduction of tacrolimus dosage
at 3rd month.
bRelated to the lack of response.
tacrolimus is effective in patients with more severe renal
insufficiency and we anticipate difficulty in dosage titra-
tion in such patients because of the narrow therapeutic
index of the drug. Finally, the optimal dosage regimen of
tacrolimus remains unclear. The current dosage appears
to be well tolerated in our patients. Whether a higher dose
of tacrolimus could be more effective but still tolerable
has to be explored in future trials.
The calcineurin inhibitors have been studied in lu-
pus nephritis. In a randomized controlled trial of 40 pa-
tients with childhood lupus nephritis, CsA microemulsion
Mok et al: Tacrolimus in lupus nephritis 817
(5 mg/kg/day) was found to be equally effective to a com-
bination of oral prednisone (2 mg/kg/day) and cyclophos-
phamide (2 mg/kg/day) at 1 year [23]. Uncontrolled stud-
ies have also shown that CsA was effective in the treat-
ment of proliferative and membranous lupus nephritis
[24, 25]. CsA was corticosteroid sparing and no change
in serum creatinine level could be demonstrated in users
after up to 4 years of therapy [24]. However, gum hyper-
trophy, hirsutism, and relapse of lupus activity when CsA
was tapered were major problems.
Drug-induced nephrotoxicity is a major concern of
the long-term use of the calcineurin inhibitors. Although
in renal transplant recipients, serum creatinine level af-
ter 5 years appears to be lower in patients treated with
tacrolimus-based than CsA-based regimens [8], long-
term data on renal function in patients with lupus nephri-
tis treated with tacrolimus are currently unknown. The
risk of calcineurin nephropathy may be reduced by main-
taining patients on a lower dose of the drugs or the se-
quential use of other immunosuppressive agents after re-
mission is achieved.
From the results of this preliminary study of tacrolimus
in lupus nephritis, there is some suggestion that neuro-
toxicity and metabolic side effects of tacrolimus might be
related to the drug level. However, there is no definite
relationship between tacrolimus level and drug efficacy.
While these observations have to be confirmed in a larger
cohort of patients, monitoring of the tacrolimus level is
essential to ensure drug compliance and reduce the inci-
dence of drug-related adverse events.
Further randomized controlled trials are clearly nec-
essary to determine the optimal dosage and duration of
tacrolimus therapy in severe lupus nephritis, as well as its
efficacy in comparison to the standard cyclophosphamide
regimens.
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